Evidence map›Paper›PMID 40205602›Full record

ArticleOrphanet journal of rare diseases2025

'We are the engine': a focus group study on clinical practice guideline development with European patient advocates for rare congenital malformations and/or intellectual disability.

Mirthe Jasmijn Klein Haneveld, Chloé Aymée de Mortier, Anne Hugon, Martina Cornelia Cornel, Charlotte Maria Wilhelmina Gaasterland, Agnies Marguerite van Eeghen

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mirthe Jasmijn Klein HaneveldAmsterdam UMC, University of Amsterdam, Emma Children's Hospital, Meibergdreef 9, Amsterdam, The Netherlands.
Chloé Aymée de MortierKnowledge Institute of the Dutch Association of Medical Specialists, Mercatorlaan 1200, 3528 BL, Utrecht, The Netherlands.
Anne HugonEuropean Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA, Clinical Genetics Department, Robert Debré University Hospital, 48 Boulevard Serurier, 75935, Paris, France.
Martina Cornelia CornelAmsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands.
Charlotte Maria Wilhelmina Gaasterland *Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Meibergdreef 9, Amsterdam, The Netherlands.
Agnies Marguerite van Eeghen *Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Meibergdreef 9, Amsterdam, The Netherlands. a.m.vaneeghen@amsterdamumc.nl.ORCID http://orcid.org/0000-0001-8149-8645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndividuals living with rare congenital malformations and/or intellectual disability often face challenges in accessing appropriate healthcare. Clinical practice guidelines (CPGs) may serve as a tool to provide evidence-based care for rare diseases, but their development is complex, and the views of affected individuals and families often remain unknown.

methodsPatient advocates of the European Reference Network ITHACA (Intellectual disability, TeleHealth, Autism and Congenital Anomalies) participated in focus groups in which their experiences with and perspectives on CPG use and development were discussed.

resultsPatient advocates considered CPGs relevant to address information and care needs and support advocacy efforts. Important characteristics included representation of heterogeneity within conditions, a holistic approach in which and how topics are addressed, user-friendly availability for individuals and families, and reliability of information. Guideline development and implementation were described as challenging, iterative processes in which effective partnership between clinicians, patient advocates, and other stakeholders is essential.

conclusionsUnderstanding the perspectives of patient advocates is essential to develop CPGs that meet the life-long and complex care needs of individuals and families living with rare conditions. Identified challenges include balancing the urgency of information needs with thorough guideline development processes, as well as the integration and interpretation of different types of knowledge.

Indexed as

Congenital AbnormalitiesIntellectual DisabilityPatient AdvocacyPractice Guidelines as TopicRare DiseasesEuropeFocus GroupsHumansClinical practice guidelinesCongenital malformationFocus groupsGenetic disorderIntellectual disabilityPatient partnershipRare disease

Identifiers

PMID40205602
PMCPMC11983842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.